Design of novel potent antihyperlipidemic agents with antioxidant/anti- inflammatory properties: Exploiting phenothiazine's strong antioxidant activity

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2568-2581

  Matralis, Alexios N ^a   Kourounakis, Angeliki P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 (10 ACETYL 2 PHENOTHIAZINYL) 4 METHYL OCTAHYDRO 1,4 BENZOXAZIN 2 OL HYDROBROMI; 2 (10 ACETYL 2 PHENOTHIAZINYL) 4 METHYLMORPHOLIN 2 OL HYDROBROMIDE; 2 HYDROXY 2 ARYL (BENZO)OXA(OR THIA)ZINE; 3 (10 ACETYL 2 PHENOTHIAZINYL)OCTAHYDRO 1,4 PYRIDO[2,1 C]OXAZIN 3 OL HYDROBROMI; 3 (10 METHYL 2 PHENOTHIAZINYL)OCTAHYDRO 1,4 PYRIDO[2,1 C]OXAZIN 3 OL HYDROBROMIDE; 3 (2 PHENOTHIAZINYL)OCTAHYDRO 1,4 PYRIDO[2,1 C]OXAZIN 3 OL HYDROBROMIDE; 4 METHYL 2 (10 METHYL 2 PHENOTHIAZINYL) MORPHOLIN 2 OL HYDROBROMIDE; 4 METHYL 2 (10 METHYL 2 PHENOTHIAZINYL)OCTAHYDRO 1,4 BENZOXAZIN 2 OL HYDROBROMI; 4 METHYL 2 (2 PHENOTHIAZINYL) 3,4 DIHYDRO 2H 1,4 BENZOTHIAZIN 2 OL; 4 METHYL 2 (2 PHENOTHIAZINYL) 3,4 DIHYDRO 2H 1,4 BENZOXAZIN 2 OL; 4 METHYL 2 (2 PHENOTHIAZINYL)MORPHOLIN 2 OL HYDROBROMIDE; 4 METHYL 2 (2 PHENOTHIAZINYL)OCTAHYDRO 1,4 BENZOXAZIN 2 OL HYDROBROMIDE; ANTILIPEMIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; INDOMETACIN; NAPROXEN; NIMESULIDE; PHENOTHIAZINE DERIVATIVE; PROBUCOL; QUERCETIN; SIMVASTATIN; SQUALENE SYNTHASE; THIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; IN VITRO STUDY; PHARMACOPHORE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ATHEROSCLEROSIS; BIPHENYL COMPOUNDS; CARRAGEENAN; CHOLESTEROL, DIETARY; CYCLOOXYGENASE INHIBITORS; DIET, HIGH-FAT; DRUG DESIGN; EDEMA; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HYPOLIPIDEMIC AGENTS; INDICATORS AND REAGENTS; LIPID PEROXIDATION; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICROSOMES; PHENOTHIAZINES; PICRATES; RATS;

EID: 84897390165     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401842e     Document Type: Article

References (50)

1. Lusis, A. J. Atherosclerosis Nature 2000, 407, 233-241
2. Berliner, J. A.; Navab, M.; Fogelman, A. M.; Frank, J. S.; Demer, L. L.; Edwards, P. A.; Watson, A. D.; Lusis, A. J. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics Circulation 1995, 91, 2488-2494
3. Libby, P. Inflammation in atherosclerosis Nature 2002, 420, 868-874
4. Galle, J.; Hansen-Hagge, T.; Wanner, C.; Seibold, S. Impact of oxidized low density lipoprotein on vascular cells Atherosclerosis 2006, 185, 219-226
5. Macrae, F.; Linton, F.; Sergio, H. Cycloxygenase-2 and inflammation in atherosclerosis Curr. Opin. Pharmacol. 2004, 4, 116-123
6. Jala, V. R.; Haribabu, B. Leucotrienes and atherosclerosis: New roles for old mediators Trends Immunol. 2004, 25, 315-322
7. Diaz, M. N.; Frei, B.; Vita, J. A.; Keaney, J. F. Antioxidants and atherosclerotic heart disease N. Engl. J. Med. 1997, 337, 408-413
8. Heinecke, J. W. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis Atherosclerosis 1998, 141, 1-15
9. Ray, W. A.; Varas-Lorenzo, C.; Chung, C. P.; Castellsague, J.; Murray, K. T.; Stein, C. M.; Daugherty, J. R.; Arbogast, P. G.; Garcia-Rodriguez, L. A. Cardiovascular risks of nonsteroidal anti-inflammatory drugs in patients after hospitalization for serious coronary heart disease Circ.: Cardiovasc. Quality Outcomes 2009, 2, 155-163
10. Hermann, M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs Curr. Rheumatol. Rep. 2009, 11, 31-35
11. Masters, B. A.; Palmoski, M. J.; Flint, O. P.; Gregg, R. E.; Wang-Iverson, D.; Durham, S. K. In vitro myotoxicity of the 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes Toxicol. Appl. Pharmacol. 1995, 131, 163-174
12. Nishimoto, T.; Tozawa, R.; Amano, Y.; Wada, T.; Imura, Y.; Sugiyama, Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors in human myocytes Biochem. Pharmacol. 2003, 66, 2133-2139
13. Davidson, M. Squalene synthase inhibition: A novel target for the management of dyslipidemia Curr. Atheroscler. Rep. 2007, 9, 78-80
14. Kourounakis, A. P.; Katselou, M. G.; Matralis, A. N.; Ladopoulou, E. M.; Bavavea, E. Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents Curr. Med. Chem. 2011, 18, 4418-4439
15. Ichikawa, M.; Yokomizo, A.; Itoh, M.; Sugita, K.; Usui, H.; Shimizu, H.; Suzuki, M.; Terayama, K.; Kanda, A. Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors Bioorg. Med. Chem. 2011, 19, 1930-1949
16. Griebenow, N.; Flessner, T.; Buchmueller, A.; Raabe, M.; Bischoff, H.; Kolkhof, P. Identification and optimization of tetrahydro-2H-3-benzazepin-2-ones as squalene synthase inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 2554-2558
17. Griebenow, N.; Buchmueller, A.; Kolkhof, P.; Schamberger, J.; Bischoff, H. Identification of 4H,6H-[2]benzoxepino[4,5-c][1,2]oxazoles as novel squalene synthase inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3648-3653
18. Ichikawa, M.; Yokomizo, A.; Itoh, M.; Haginoya, N.; Sugita, K.; Usui, H.; Terayama, K.; Kanda, A. Discovery of atrop fixed alkoxy-aminobenhydrol derivatives: Novel, highly potent and orally efficacious squalene synthase inhibitors Bioorg. Med. Chem. 2011, 19, 5207-5224
19. Ichikawa, M.; Ohtsuka, M.; Ohki, H.; Haginoya, N.; Itoh, M.; Sugita, K.; Usui, H.; Suzuki, M.; Terayama, K.; Kanda, A. Discovery of novel tricyclic compounds as squalene synthase inhibitors Bioorg. Med. Chem. 2012, 20, 3072-3093
20. Chrysselis, M. C.; Rekka, E. A.; Kourounakis, A. P. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity J. Med. Chem. 2000, 43, 609-612
21. Kourounakis, A. P.; Matralis, A. N.; Nikitakis, A. Design of more potent squalene synthase inhibitors with multiple activities Bioorg. Med. Chem. 2010, 18, 7402-7412
22. Rankin, G. O.; Riley, T. N.; Murphy, J. C. 3-Aryl- and 3-hydroxy-3-aryloctahydropyrido[2,1-c][1,4]oxazines. Synthesis, stereochemistry, and central nervous system pharmacological actions J. Med. Chem. 1978, 21, 460-464
23. Matralis, A. N.; Katselou, M. G.; Nikitakis, A.; Kourounakis, A. P. Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents J. Med. Chem. 2011, 54, 5583-5591
24. Jaszczyczyn, A.; Gasiorowski, K.; Swiatek, P.; Malinka, W.; Cieoelik-Boczula, K.; Petrus, J.; Czarnik-Matusewicz, B. Chemical structure of phenothiazines and their biological activity Pharmacol. Rep. 2012, 64, 16-23
25. Yu, M. J.; McCowan, J. R.; Thrasher, K. J.; Keith, P. T.; Luttman, C. A.; Ho, P. P.; Towner, R. D.; Bertsch, B.; Horng, J. S.; Um, S. L.; Phebus, L. A.; Saunders, R. D. Phenothiazines as lipid peroxidation inhibitors and cytoprotective agents J. Med. Chem. 1992, 35, 716-724
26. Federsel, H. J.; Glasare, G.; Hogstrom, C.; Wiestbl, J.; Zinko, B.; Odman, C. A convenient quaternization rearrangement procedure for conversion of thiazoles to medium- and large-sized N,S-heterocycles J. Org. Chem. 1995, 60, 2597-2606
27. Liu, Z. Q.; Tang, Y. Z.; Wu, D. Antioxidant effects of phenothiazine, phenoxazine, and iminostilbene on free-radical-induced oxidation of linoleic acid and DNA J. Phys. Org. Chem. 2009, 22, 1009-1014
28. Jeong, T. S.; Kim, K. S.; Kim, J. R.; Cho, K. H.; Lee, S.; Lee, W. S. Novel 3,5-diaryl pyrazolines and pyrazoles as low-density lipoprotein (LDL) oxidation inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 2719-2723
29. Pandit, J.; Danley, D. E.; Schulte, G. K.; Mazzalupo, S.; Pauly, T. A.; Hayward, C. M.; Hamanaka, E. S.; Thompson, J. F.; Harwood, H. J., Jr. Crystal structure of human squalene synthase: A key enzyme in cholesterol biosynthesis J. Biol. Chem. 2000, 275, 30610-30617
30. Stewart, K. D.; Loren, S.; Frey, L.; Otis, E.; Klinghofer, V.; Hulkower, K. I. Discovery of a new cycloxygenase-2 lead compound through 3-D database searching and combinatorial chemistry Bioorg. Med. Chem. Lett. 1998, 8, 529-534
31. Taraporewala, I.; Kauffman, J. M. Synthesis and structure-activity relationships of anti-inflammatory 9,10-dihydro-9-oxo-2-acridine-alcanoic acids and 4-(2-carboxyphenyl)aminobenzenealcanoic acids J. Pharm. Sci. 1990, 79, 173-178
32. Hadjipetrou-Kourounakis, L.; Rekka, E.; Kourounakis, A. Suppression of adjuvant induced disease (AID) by a novel analgesic-opioid agonist which also possesses antioxidant activity Ann. N.Y. Acad. Sci. 1992, 650, 19-24
33. Hiyoshi, H.; Yanagimachi, M.; Ito, M.; Saeki, T.; Yoshida, I.; Okada, T.; Ikuta, H.; Shinmyo, D.; Tanaka, K.; Kurusu, N.; Tanaka, H. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism Eur. J. Pharmacol. 2001, 431, 345-352
34. Hiyoshi, H.; Yanagimachi, M.; Ito, M.; Yasuda, N.; Okada, T.; Ikuta, H.; Shimnyo, D.; Tanaka, K.; Kurusu, N.; Yoshida, I.; Abe, S.; Saeki, T.; Tanaka, H. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol patway in rat hepatocytes J. Lipid Res. 2003, 44, 128-135
35. Pazzucconi, F.; Dorigotti, F.; Gianfranceschi, G.; Campagnoli, G.; Sirtori, M.; Franceschini, G.; Sirtori, C. R. Therapy with HMG CoA reductase inhibitors: Characteristics of the long-term permanence of hypocholesterolemic activity Atherosclerosis 1995, 117, 189-198
36. Ugawa, T.; Kakuta, H.; Moritani, H.; Shikama, H. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model Br. J. Pharmacol. 2002, 135, 1572-1578
37. Trivedi, B. K.; Purchase, T. S.; Holmes, A.; Augelli-Szafran, C. E.; Essenburg, A. D.; Hamelehle, K. L.; Stanfield, R. L.; Bousley, R. F.; Krause, B. R. Inhibitors of acyl-CoA: Cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N′-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity J. Med. Chem. 1994, 37, 1652-1659
38. La, Y. J.; Wan, C. L.; Zhu, H.; Yang, Y. F.; Chen, Y. S.; Pan, Y. X.; Feng, G. Y.; He, L. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients J. Neural Transm. 2007, 114, 657-663
39. Meng, Q. H.; Bergeron, L.; Sparks, D. L.; Marcel, Y. L. Role of apolipoprotein A-I in cholesterol transfer between lipoproteins. Evidence for involvement of specific apoA-I domains J. Biol. Chem. 1995, 270, 8588-8596
40. Bauer, H.; Stier, F.; Petry, C.; Knorr, A.; Stadler, C.; Staab, H. Phenothiazine-bipyridinium cyclophanes Eur. J. Org. Chem. 2001, 3255-3278
41. Massie, S.; Cooke, I.; Hills, W. A. Ring derivatives of phenothiazine. 11. 2-Phenothiazinyl ketones and their derivatives J. Org. Chem. 1956, 21, 1006-1008
42. Sutton, B.; Birxie, J. Phenothiazine-1-carboxylic acids J. Med. Chem. 1966, 9, 835-837
43. Burger, A.; Clements, J. P. Some derivatives of phenothiazine J. Org. Chem. 1954, 19, 1113-1116
44. Bahner, C. T.; Pickens, D.; Bettis Bales, D. Some quaternary ammonium salts of substituted thiazoles J. Am. Chem. Soc. 1948, 70, 1652-1654
45. Tsuge, O.; Shimoharada, H.; Noguchi, M. Cycloaddition of benzothiazolium N-phenacylide with olefinic dipolarophiles Heterocycles 1981, 15, 807-814
46. Blois, M. S. Antioxidant determinations by the use of a stable free radical Nature 1958, 181, 1199-1200
47. Havel, R. J.; Eder, H. A.; Bragdon, J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J. Clin. Invest. 1955, 34, 1345-1363
48. Kuroda, M. K.; Tanzawa, K.; Tsujita, Y.; Endo, A. Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in triton WR-1339-induced hyperlipidemia Biochim. Biophys. Acta 1977, 489, 119-125
49. Esterbauer, H.; Cheesemon, K. H. Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxynonenal Methods Enzymol. 1990, 186, 407-421
50. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folin phenol reagent J. Biol. Chem. 1951, 193, 265-275